New scheme of dyslipidemia, the third indication of PCSK9 inhibitor approved by Amgen

On December 10, in Shanghai, China, Amgen announced that, according to the approval results of the State Drug Administration, ribeian ® (erloyuzumab injection) has been approved for a broader indication on November 22, 2019, becoming the first PCSK9 inhibitor approved for use in adult patients with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia in China 。 Elouzumab is an innovative lipid-lowering drug It can increase the number of LDLR that can clear LDL in the blood by inhibiting the binding of procrotein converting enzyme (PCSK9) to LDLR, thus reducing the level of LDL-C in patients This approval further expands the indications of eloyumab, which can be used as dietary adjuvant therapy in adult patients with primary hypercholesterolemia (heterozygous familial and non familial) or mixed dyslipidemia, to reduce LDL-C level: including in patients who are still unable to achieve LDL-C target after receiving the most tolerable dose of statins, and statins , or in combination with statins and other lipid-lowering therapies, or in patients with intolerance or contraindications of statins, alone or in combination with other lipid-lowering therapies This is the third indication of eloyumab approved in China Rebeccan ® has been approved by the State Drug Administration on July 31, 2018 for homozygous familial hypercholesterolemia in adults or adolescents over 12 years old; and approved on January 28, 2019 for adult patients with atherosclerotic cardiovascular disease to reduce the risk of myocardial infarction, stroke and coronary revascularization Important product information ribeian ® (eloutab injection) has been approved in China for: 1 Reducing the risk of cardiovascular events: reducing the risk of myocardial infarction, stroke and coronary revascularization in adult patients with atherosclerotic cardiovascular disease By: - in combination with a maximum tolerable dose of statins, with or without other lipid lowering therapies -In patients with intolerant or contraindicated use of statins, they were treated alone or in combination with other lipid-lowering therapies 2 Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed type dyslipidemia: it can be used as an auxiliary therapy of diet, for the treatment of adult primary hypercholesterolemia (heterozygous familial and non familial) or mixed type dyslipidemia, to reduce the level of LDL-C homozygous familial hypercholesterolemia: -In patients with LDL-C target that can not be achieved after receiving the maximum tolerable dose of statins, they should be combined with statins, or with statins and other lipid-lowering therapies -In patients with intolerant or contraindicated use of statins, they were treated alone or in combination with other lipid-lowering therapies 3 Homozygous familial hypercholesterolemia: it is used for homozygous familial hypercholesterolemia of adults or adolescents over 12 years old It can be used in combination with diet therapy and other LDL-C reduction therapies (such as statins, ezemeb, LDL separation) for patients with homozygous familial hypercholesterolemia (hofh) who need further LDL-C reduction Adorable adorable